General Biologic, established in 2002 and based in Shanghai, provides professional services focused on China’s biotechnology, pharmaceutical, and healthcare industries. GB offers clients information, analysis, and advice that enables confident and informed decision making. Services and products include: Consulting: A partner with a proven track record, access to industry relationships, and practical experience is necessary to understand and seize opportunities in China. Focus areas: Market and competitor research Strategic due diligence Partner screening, selection, and negotiation Strategic and tactical planning for China entry Assessment of technologies and R&D outsourcing opportunities Advisory services: Strong local relationships built over years on the ground in China are critical to accessing quality investment and licensing opportunities. GB provides unparalleled access in the following focus areas: Providing investment opportunities to private equity and venture capital clients Working with corporations to assess, screen, and acquire China’s domestic enterprises Seeking out and evaluating licensing/co-development opportunities Information products: Collecting accurate, high-quality information is a difficult, expensive, and time-consuming task in China. GB systematically tracks and analyzes China’s bio-business industry and publishes reports and data products critical for making informed decisions. Unique information resources include: The China Pharmaceutical & Biotechnology Monthly- a comprehensive review of each month’s events in the healthcare and pharma space including deals, regulatory announcements, licensing and collaborations as well as people and company profiles and in-depth lead articles focusing on topics relevant to the industry Podcast Series - interviews with important figures in China’s healthcare and pharmaceutical industries Industry reports - primary research focusing on biopharma and life science industry sub-sectors, including extensive analyses, case studies, forecasts, and listings